Literature DB >> 23404370

Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations.

David E Reuss1, Rosario M Piro, David T W Jones, Matthias Simon, Ralf Ketter, Marcel Kool, Albert Becker, Felix Sahm, Stefan Pusch, Jochen Meyer, Christian Hagenlocher, Leonille Schweizer, David Capper, Phillipp Kickingereder, Jana Mucha, Christian Koelsche, Natalie Jäger, Thomas Santarius, Patrick S Tarpey, Philip J Stephens, P Andrew Futreal, Ruth Wellenreuther, Jürgen Kraus, Doris Lenartz, Christel Herold-Mende, Christian Hartmann, Christian Mawrin, Nathalia Giese, Roland Eils, V Peter Collins, Rainer König, Otmar D Wiestler, Stefan M Pfister, Andreas von Deimling.   

Abstract

Meningiomas are among the most frequent intracranial tumors. The secretory variant of meningioma is characterized by glandular differentiation, formation of intracellular lumina and pseudopsammoma bodies, expression of a distinct pattern of cytokeratins and clinically by pronounced perifocal brain edema. Here we describe whole-exome sequencing analysis of DNA from 16 secretory meningiomas and corresponding constitutional tissues. All secretory meningiomas invariably harbored a mutation in both KLF4 and TRAF7. Validation in an independent cohort of 14 secretory meningiomas by Sanger sequencing or derived cleaved amplified polymorphic sequence (dCAPS) assay detected the same pattern, with KLF4 mutations observed in a total of 30/30 and TRAF7 mutations in 29/30 of these tumors. All KLF4 mutations were identical, affected codon 409 and resulted in a lysine to glutamine exchange (K409Q). KLF4 mutations were not found in 89 non-secretory meningiomas, 267 other intracranial tumors including gliomas, glioneuronal tumors, pituitary adenomas and metastases, 59 peripheral nerve sheath tumors and 52 pancreatic tumors. TRAF7 mutations were restricted to the WD40 domains. While KLF4 mutations were exclusively seen in secretory meningiomas, TRAF7 mutations were also observed in 7/89 (8 %) of non-secretory meningiomas. KLF4 and TRAF7 mutations were mutually exclusive with NF2 mutations. In conclusion, our findings suggest an essential contribution of combined KLF4 K409Q and TRAF7 mutations in the genesis of secretory meningioma and demonstrate a role for TRAF7 alterations in other non-NF2 meningiomas.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23404370     DOI: 10.1007/s00401-013-1093-x

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  80 in total

Review 1.  Advances in meningioma genetics: novel therapeutic opportunities.

Authors:  Matthias Preusser; Priscilla K Brastianos; Christian Mawrin
Journal:  Nat Rev Neurol       Date:  2018-01-05       Impact factor: 42.937

2.  Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas.

Authors:  Shuyu Hao; Guanyou Huang; Jie Feng; Da Li; Ke Wang; Liang Wang; Zhen Wu; Hong Wan; Liwei Zhang; Junting Zhang
Journal:  J Neurooncol       Date:  2019-06-08       Impact factor: 4.130

3.  Clinical impact of targeted amplicon sequencing for meningioma as a practical clinical-sequencing system.

Authors:  Sayaka Yuzawa; Hiroshi Nishihara; Shigeru Yamaguchi; Hiromi Mohri; Lei Wang; Taichi Kimura; Masumi Tsuda; Mishie Tanino; Hiroyuki Kobayashi; Shunsuke Terasaka; Kiyohiro Houkin; Norihiro Sato; Shinya Tanaka
Journal:  Mod Pathol       Date:  2016-04-22       Impact factor: 7.842

4.  DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management.

Authors:  Farshad Nassiri; Yasin Mamatjan; Suganth Suppiah; Jetan H Badhiwala; Sheila Mansouri; Shirin Karimi; Olli Saarela; Laila Poisson; Irina Gepfner-Tuma; Jens Schittenhelm; Ho-Keung Ng; Houtan Noushmehr; Patrick Harter; Peter Baumgarten; Michael Weller; Matthias Preusser; Christel Herold-Mende; Marcos Tatagiba; Ghazaleh Tabatabai; Felix Sahm; Andreas von Deimling; Gelareh Zadeh; Kenneth D Aldape
Journal:  Neuro Oncol       Date:  2019-07-11       Impact factor: 12.300

5.  SMO mutant olfactory groove meningiomas-the next in line for targeted therapy.

Authors:  Christopher Alvarez-Breckenridge; Priscilla K Brastianos
Journal:  Neuro Oncol       Date:  2017-03-01       Impact factor: 12.300

6.  Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design.

Authors:  Richard G Everson; Yuuri Hashimoto; Jacob L Freeman; Tiffany R Hodges; Jason Huse; Shouhao Zhou; Joanne Xiu; David Spetzler; Nader Sanai; Lyndon Kim; Santosh Kesari; Andrew Brenner; Franco De Monte; Amy Heimberger; Shaan M Raza
Journal:  J Neurooncol       Date:  2018-05-30       Impact factor: 4.130

7.  Clinical features, surgical management, and prognostic factors of secretory meningiomas: a single-center case series of 149 patients.

Authors:  Xiaogang Tao; Kun Wang; Jinqian Dong; Zonggang Hou; Zhen Wu; Junting Zhang; Baiyun Liu
Journal:  J Neurooncol       Date:  2017-11-15       Impact factor: 4.130

8.  Advances in multidisciplinary therapy for meningiomas.

Authors:  Priscilla K Brastianos; Evanthia Galanis; Nicholas Butowski; Jason W Chan; Ian F Dunn; Roland Goldbrunner; Christel Herold-Mende; Franziska M Ippen; Christian Mawrin; Michael W McDermott; Andrew Sloan; James Snyder; Ghazaleh Tabatabai; Marcos Tatagiba; Joerg C Tonn; Patrick Y Wen; Kenneth Aldape; Farshad Nassiri; Gelareh Zadeh; Michael D Jenkinson; David R Raleigh
Journal:  Neuro Oncol       Date:  2019-01-14       Impact factor: 12.300

9.  Molecular and translational advances in meningiomas.

Authors:  Suganth Suppiah; Farshad Nassiri; Wenya Linda Bi; Ian F Dunn; Clemens Oliver Hanemann; Craig M Horbinski; Rintaro Hashizume; Charles David James; Christian Mawrin; Houtan Noushmehr; Arie Perry; Felix Sahm; Andrew Sloan; Andreas Von Deimling; Patrick Y Wen; Kenneth Aldape; Gelareh Zadeh
Journal:  Neuro Oncol       Date:  2019-01-14       Impact factor: 12.300

10.  Genetic profiling by single-nucleotide polymorphism-based array analysis defines three distinct subtypes of orbital meningioma.

Authors:  Cheng-Ying Ho; Stacy Mosier; Janice Safneck; Diva R Salomao; Neil R Miller; Charles G Eberhart; Christopher D Gocke; Denise A S Batista; Fausto J Rodriguez
Journal:  Brain Pathol       Date:  2014-05-21       Impact factor: 6.508

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.